Senti Biosciences (NASDAQ:SNTI) Issues Quarterly Earnings Results

Senti Biosciences (NASDAQ:SNTIGet Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, Zacks reports.

Senti Biosciences Stock Performance

Shares of SNTI traded down $0.11 during trading hours on Thursday, hitting $3.51. The stock had a trading volume of 16,781 shares, compared to its average volume of 781,284. The company’s fifty day simple moving average is $3.95 and its 200 day simple moving average is $3.44. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94. The firm has a market cap of $16.95 million, a P/E ratio of -0.23 and a beta of 2.52.

Analysts Set New Price Targets

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a research report on Monday, December 2nd.

Read Our Latest Report on SNTI

Senti Biosciences Company Profile

(Get Free Report)

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

Featured Articles

Earnings History for Senti Biosciences (NASDAQ:SNTI)

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.